Ventipulmin for Horses | 
Ventipulmin is a drug used to open the respiratory passages of horses and to help clear them of mucus. This can be beneficial in some allergic respiratory diseases, often associated with a cough, due to mould spores in hay and straw (chronic obstructive pulmonary disease or COPD). Ventipulmin is also useful in cases where infection of the respiratory tract is involved, such as equine influenza. Where bacterial infection is present, antibiotics can be used as well. Ventipulmin is available as Ventipulmin Granules or Ventipulmin Syrup to add to food. There is also a Ventipulmin Injection available.
| | | | |
|  | Customers who purchased these items also purchased |   | | Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction 
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
White granules. Each gram of granules contains 16 micrograms of clenbuterol hydrochloride.
Uses
Treatment of respiratory disease in horses where airway obstruction due to bronchospasm and/or accumulation of mucus is a contributing factor, and improved mucociliary clearance is desirable. To be used alone or as adjuvant therapy.
In particular:
1.Acute, sub-acute and chronic infections where the presence of mucus and/or micro-organisms may stimulate bronchospasm or cause airway obstruction and thus increase airway resistance. For example, bronchitis, bronchiolitis and bronchopneumonia alone, or associated with equine influenza and other viral respiratory diseases.
2.Acute, sub-acute and chronic respiratory allergies.
3.Chronic Obstructive Pulmonary Disease (COPD).
In cases accompanied by bacterial infection the administration of antimicrobial agents is recommended.
Dosage and administration
Administer 5 g Ventipulmin Granules per 100 kg bodyweight twice daily.
This is equivalent to twice daily administration of 0.8 micrograms clenbuterol per kg bodyweight.
The granules should be added to the feed. A measuring scoop is provided with the 500 g pack. When full, the scoop contains 10 g. A scored line on the scoop indicates a half measure (5 g). Add to feed immediately before administration. Discard any remaining medicated feed.
Treatment should continue for as long as necessary.
Contra-indications, warnings, etc
Known hypersensitivity to the active ingredient. Clenbuterol may cause side effects such as sweating (mainly neck region), muscle tremor, tachycardia, slight hypotension or restlessness. These are typical for β-agonists and occur rarely.
Ventipulmin antagonises the effects of prostaglandin F2α and oxytocin.
Ventipulmin is antagonised by β-adrenergic blocking agents.
If used during pregnancy, treatment must be discontinued at the expected time of delivery since uterine contractions may be abolished under its influence.
Dosages of clenbuterol hydrochloride up to 4 times the therapeutic dose (administered orally) for a period of 90 days caused transient side effects typical for beta2-adrenoceptor agonists (sweating, tachycardia, muscle tremor), which required no treatment. In case of accidental overdose, a β-blocker (such as propranolol) may be used as antidote.
Withdrawal period
Animals must not be slaughtered for human consumption during treatment. Horses may be slaughtered for human consumption only after 28 days from the last treatment.
This product contains clenbuterol, a β-agonist. Take care to avoid skin contact. In case of skin contact wash affected area thoroughly. If irritation occurs/persists seek medical advice. Take care to avoid accidental eye contact. In the case of accidental eye contact, flush thoroughly with clean water and seek medical advice. When using do not eat, drink or smoke. Wash hands thoroughly after using the product. Avoid inhaling dust.
Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
For animal treatment only. Keep out of the reach and sight of children.
Pharmaceutical precautions
Protect from light. Do not store above 30°C.
Legal category
POM-V
Packaging Quantities
Screw top polythene bottle containing 500 g granules.
Further information
The product contains the active ingredient clenbuterol hydrochloride which is a sympathomimetic amine with a high degree of selectivity for the B2-receptor sites in the body, thus providing intense bronchodilating properties with minimum effect on the cardiovascular system. It has been shown to stimulate mucociliary clearance in horses.
The effects on pulmonary function and clinical response have been assessed in clinical trials with horses suffering from a variety of respiratory conditions.
A marked decrease in intrathoracic pressure, a decrease in respiratory rate, an initial decrease followed by an increase in arterial oxygen partial pressure and clinical improvements were observed.
In addition, a significant reduction in resistance to airflow and a clinical improvement in the animals respiratory pattern were seen.
The active substance is well absorbed following oral administration. Oral and parenteral dose rates are identical at 0.08 micrograms per kg bodyweight.
Marketing authorisation number
Vm 00015/4040.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
A clear, colourless aqueous solution for injection. Each ml contains 30 micrograms clenbuterol hydrochloride and 10 mg benzyl alcohol as preservative.
Uses
Treatment of respiratory disease in horses where airway obstruction due to bronchospasm and/or accumulation of mucus is a contributing factor, and improved mucociliary clearance is desirable. To be used alone or as adjuvant therapy.
In particular:
1.Acute, sub-acute and chronic infections where the presence of mucus and/or micro-organisms may stimulate bronchospasm or cause airway obstruction and thus increase airway resistance. For example, bronchitis, bronchiolitis and bronchopneumonia alone, or associated with equine influenza and other viral respiratory diseases.
2.Acute, sub-acute and chronic respiratory allergies.
3.Chronic obstructive pulmonary disease (COPD).
In cases accompanied by bacterial infection the administration of anti microbial agents is recommended.
Dosage and administration
By slow intravenous injection. Twice daily administration of 2.7 ml of the injection per 100 kg bodyweight. This is equivalent to twice daily administration of 0.8 micrograms of clenbuterol hydrochloride per kg bodyweight. Treatment should continue for as long as necessary. Avoid the introduction of contamination during use.
Contra-indications, warnings, etc
Ventipulmin antagonises the effects of prostaglandin F2-alpha and oxytocin.
Ventipulmin is antagonised by beta-adrenergic blocking agents.
If used during pregnancy, treatment must be discontinued at the expected time of delivery since uterine contractions may be abolished under its influence.
Withdrawal period
Animals must not be slaughtered for human consumption during treatment. Horses may be slaughtered for human consumption only after 28 days from the last treatment.
Do not use in cases of known sensitivity to clenbuterol. Sweating and transient mild muscle tremor may occur after intravenous administration in some horses. It is suggested that a may be responsible for this, causing transient peripheral vasodilation.
Vasodilation is a feature of all beta-adrenergic drugs to a greater or lesser degree and may be minimised by administering Ventipulmin slowly.
This product contains clenbuterol, a beta-agonist. Take care to avoid skin contact. In case of skin contact wash affected area thoroughly. If irritation occurs/persists seek medical advice. Take care to avoid accidental eye contact. In the case of accidental eye contact, flush thoroughly with clean water and seek medical advice. When using do not eat, drink or smoke. Wash hands thoroughly after using the product.
Accidental self-injection may produce tachycardia and tremor. These effects may be reversed by the use of a non-selective beta-blocker. If accidental self-injection occurs seek medical advice immediately, avoiding driving if possible
Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
For animal treatment only. Keep out of the reach and sight of children.
Pharmaceutical precautions
Do not store above 25°C. Protect from light. Following withdrawal of the first dose use the product within one month. Discard unused material. Avoid the introduction of contamination during use. Should any growth or discolouration occur the product should be discarded.
Legal category
POM-V
Packaging Quantities
Amber vials with pink bromobutyl stoppers containing 50 ml of solution.
Further information
The product contains the active ingredient clenbuterol hydrochloride, which is a sympathomimetic amine with a high degree of selectivity for the B2-receptor sites in the body, thus providing intense bronchodilating properties with minimum effect on the cardiovascular system. It has been shown to stimulate muco-ciliary clearance in horses.
The effects on pulmonary function and clinical response have been assessed in clinical trials with horses suffering from a variety of respiratory conditions.
A marked decrease in intrathoracic pressure, a decrease in respiratory rate, an initial decrease followed by an increase in arterial oxygen partial pressure and clinical improvements were observed. In addition, a significant reduction in resistance to airflow and a clinical improvement in the animals respiratory pattern were seen.
Marketing authorisation number
Vm 00015/4039.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Boehringer Ingelheim Limited
Address: Ellesfield Avenue
Bracknell
Berkshire RG12 8YS
Telephone: Sales & Marketing Enquiries 01344 746959
Telephone: Technical Enquiries 01344 746957
Fax: 01344 741349
Presentation
A clear colourless syrup. Each ml contains 25 micrograms clenbuterol hydrochloride as active ingredient plus 1.8 mg methyl parahydroxybenzoate and 0.2 mg propyl parahydroxybenzoate as preservatives.
Uses
Treatment of respiratory disease in horses where airway obstruction due to bronchospasm and/or accumulation of mucus is a contributing factor and improved mucociliary clearance is desirable. To be used alone or as adjuvant therapy.
In particular:
1.Acute, sub-acute and chronic infections where the presence of mucus and/or micro-organisms may stimulate bronchospasm or cause airway obstruction and thus increase airway resistance. For example, bronchitis, bronchiolitis and bronchopneumonia alone, or associated with equine influenza and other viral respiratory diseases.
2.Acute, sub-acute and chronic respiratory allergies.
3.Chronic Obstructive Pulmonary Disease (COPD).
In cases accompanied by bacterial infection the concurrent administration of antimicrobial agents is recommended.
Dosage and administration
For Oral Use. Twice daily administration of 4 ml Ventipulmin Syrup per 125 kg bodyweight.
This is equivalent to twice daily administration of 0.8 micrograms clenbuterol hydrochloride/kg bodyweight.
The syrup should be added to the feed (one depression of the pump delivers 4 ml syrup).
Treatment should continue for as long as necessary.
Contra-indications, warnings, etc
Known hypersensitivity to the active ingredient or any of the excipients. Clenbuterol may cause side effects such as sweating (mainly neck region), muscle tremor, tachycardia, slight hypotension or restlessness. These are typical for β-agonists and occur rarely.
Do not use in horses with known cardiac disease.
Ventipulmin antagonises the effects of prostaglandin F2α and oxytocin.
Ventipulmin is antagonised by β-adrenergic blocking agents.
If used during pregnancy, treatment must be discontinued at the expected time of delivery since uterine contractions may be abolished under its influence.
Dosages of clenbuterol hydrochloride up to 4 times the therapeutic dose (administered orally) for a period of 90 days caused transient side effects typical for beta2-adrenoceptor agonists (sweating, tachycardia, muscle tremor), which required no treatment. In case of accidental overdose, a β-blocker (such as propranolol) may be used as antidote.
Withdrawal period
Animals must not be slaughtered for human consumption during treatment. Horses may be slaughtered for human consumption only after 28 days from the last treatment.
This product contains clenbuterol, a β-agonist. Take care to avoid skin contact. In case of skin contact wash affected area thoroughly. If irritation occurs/persists seek medical advice. Take care to avoid accidental eye contact. In the case of accidental eye contact, flush thoroughly with clean water and seek medical advice. When using do not eat, drink or smoke. Wash hands thoroughly after using the product.
Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
For animal treatment only. Keep out of the reach and sight of children.
Pharmaceutical precautions
Do not store above 25°C. Protect from light. Following opening of the pack use the product within 30 days. Discard unused material.
Legal category
POM-V
Packaging Quantities
Screw top polythene bottle containing 355 ml syrup with 4 ml pump dispenser.
Further information
Ventipulmin contains clenbuterol hydrochloride, which is a sympathomimetic amine which preferentially binds to symbol B2 adrenoreceptors on cell membranes of the bronchi. This subsequently activates the enzyme adenylate cyclase in smooth muscle cells, thus providing intense bronchodilating properties and decreasing airway resistance with minimum effect on the cardiovascular system. Ventipulmin has been shown to inhibit histamine release from mast cells in the lungs, and enhance mucociliary clearance in horses.
After oral administration in horses, clenbuterol is readily absorbed and maximum plasma concentrations reached within 2 hours of dosing. Steady state level in plasma are reached after 3-5 days treatment and range from 1.0 – 2.2 ng/ml.
The substance is rapidly distributed in tissues and metabolised primarily by the liver. Clenbuterol is the main excretory product and approximately 45% of the dose is eliminated unchanged in the urine. The kidneys excrete 70 – 91% of the total dose, and the remainder is eliminated in the faeces (6 – 15%).
Marketing authorisation number
Vm 00015/4032.
| 
